home / stock / nvcr / nvcr news


NVCR News and Press, NovoCure Limited From 05/02/24

Stock Information

Company Name: NovoCure Limited
Stock Symbol: NVCR
Market: NASDAQ
Website: novocure.com

Menu

NVCR NVCR Quote NVCR Short NVCR News NVCR Articles NVCR Message Board
Get NVCR Alerts

News, Short Squeeze, Breakout and More Instantly...

NVCR - NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript

2024-05-02 11:43:08 ET NovoCure Limited (NVCR) Q1 2024 Earnings Conference Call May 02, 2024 08:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief F...

NVCR - Novocure secures new $400M multi-tranche debt financing, shares up

2024-05-02 07:51:28 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $13...

NVCR - NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $138.5M beats by $7.05M

2024-05-02 07:07:02 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure Q1 2024 Earnings Preview Novocure climbs ...

NVCR - Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 milli...

NVCR - Novocure Reports First Quarter 2024 Financial Results

Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR...

NVCR - NovoCure Q1 2024 Earnings Preview

2024-05-01 11:42:47 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation Novocure climbs after late-stage win for lung cancer thera...

NVCR - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

NVCR - Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...

NVCR - Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, i...

NVCR - NVCR, SBNY and VITL are among after hour movers

2024-04-01 17:08:57 ET Gainers: Zapata Computing  (ZPTA) +12% . Thoughtworks Holding ( TWKS ) +4% . Gain Therapeutics ( GANX ) +3% . Portillo's ( PTLO ) +3% . Vital Farms ( VITL ) +3% . Losers: Signature Bank ( OTC:SBN...

Previous 10 Next 10